Anders Elias Hansen

CarboCell Antibiotics - Precision Delivery: Transforming Surgical Outcomes, Reducing Costs, Saving Lives

Anders and team

From left to right: Catrine Jyde Berthelsen, Jonas R Henriksen, Anders E Hansen, and Niranjan Kotla.



Applicant

Anders Elias Hansen.


Project drescription

Every patient faces the risk of Surgical Site Infections (SSIs) and meanwhile Antimicrobial Resistance (AMR) is rapidly worsening, challenging treatment outcomes and healthcare economics.

This urgent situation demands effective antimicrobial therapies.

CarboCell antibiotics can revolutionize surgical outcomes, cut costs, and save lives by preventing and treating SSIs and localized infections. Our lead drug candidate enhances the potency of existing antibiotics through precision and sustained delivery to surgical site and localized infections. In advanced preclinical pig models, we have demonstrated completely unprecedented therapeutic efficacy and outperform market leading technologies.

In the SPARK program, we will expand our preclinical data and refine regulatory and clinical strategies to launch a spin-off company.


Institution

Technical University of Denmark.